Evidence guide · UAE

SS-31 (elamipretide): the approved mitochondrial peptide behind the anti-ageing hype

SS-31 (elamipretide) has a US approval, for an ultra-rare disease. What the trials, the mouse ageing and fertility studies and the FDA's warning letters to online sellers show.

Review type: research summary. This page summarises published research and product labels, cited below.

SS-31, also called elamipretide, is a small peptide that targets mitochondria, the energy-producing parts of cells. It is sold online as a "research" peptide, and a study published in Aging Cell in October 2026 adds a new angle: a seven-day course of injections improved fertility and egg quality in older female mice, and the peptide improved the maturation of human eggs in the lab. Unlike many peptides sold online, elamipretide is also a real prescription medicine. In September 2025 the US Food and Drug Administration (FDA) gave it accelerated approval, as Forzinity, for Barth syndrome, an ultra-rare inherited mitochondrial disease. In August 2026 the FDA sent warning letters to three online sellers, saying their "SS-31 (Elamipretide)" products were unapproved new drugs.

Short answer: elamipretide is a genuine drug with a narrow, conditional approval based on a very small number of patients. In larger trials in other conditions it missed its main goals. The anti-ageing case rests on animal studies and a single-dose study in older adults that raised a lab measure of muscle energy without making muscles less fatigable. The fertility study is in mice and in eggs in a dish, not in women trying to conceive. A "research" vial bought online is not Forzinity. Do not inject it.

What elamipretide is

Elamipretide is a four-amino-acid peptide, developed under the names SS-31, MTP-131 and Bendavia, that binds cardiolipin, a lipid found in the inner membrane of mitochondria. A 2025 review in the International Journal of Molecular Sciences describes it stabilising the folded structure of that membrane, reducing oxidative stress and supporting the production of ATP, the cell's energy currency. The preclinical studies it cites span models of heart failure, neurodegeneration and muscle weakness.

The approval: what it rests on

The FDA approved Forzinity on 19 September 2025 for adults and children with Barth syndrome who weigh at least 30 kg, to improve muscle strength. According to the prescribing information, the programme involved 12 male patients. In the randomised, double-blind, placebo-controlled crossover phase, 12 weeks on the drug was not superior to placebo on its main measures, the six-minute walk distance and a fatigue score, and knee muscle strength did not increase. Strength gains appeared in the open-label extension, in which everyone received the drug: the median change in knee extensor strength was 63 newtons at week 168, in the 8 patients who reached that point, from a starting median of 124 newtons. The FDA accepted that improvement as reasonably likely to predict real benefit, such as standing more easily or walking farther, and requires a new randomised, placebo-controlled trial to confirm it.

The label lists injection-site reactions as the most common side effect: redness at the injection site affected all 12 patients on the drug, against 3 of 12 on placebo. It also warns of hypersensitivity reactions, including serious allergic reactions that needed emergency treatment, which may occur within minutes to months of starting.

The trials it missed

  • MMPOWER-3 (Neurology, 2023): 218 adults with genetically confirmed primary mitochondrial myopathy received 40 mg a day under the skin or placebo for 24 weeks. The trial did not meet its primary endpoints. The difference in six-minute walk distance between groups was -3.2 metres (95% CI -18.7 to 12.3). A later post hoc analysis suggested a benefit in people with particular genetic subtypes, and the authors describe a follow-up phase 3 trial designed to look at those patients.
  • ReCLAIM-2 (Ophthalmology Science, 2025): 176 people aged 55 or over with dry age-related macular degeneration and geographic atrophy received daily injections or placebo for 48 weeks. Elamipretide did not meet its primary endpoints for low-light vision or the growth of atrophy. Some other predefined retinal measures favoured the drug, with nominal p-values. Adverse events were reported in 86% of people on elamipretide and 71% on placebo, mostly injection-site reactions.

The ageing and fertility research

  • Older adults (PLoS One, 2021): 39 healthy people aged 60 to 85 who had poorly functioning mitochondria in a hand muscle received a single two-hour infusion of elamipretide or placebo. Maximum mitochondrial ATP production in the muscle rose immediately afterwards (p = 0.055 for the absolute change, p = 0.045 for the percentage change), was no different by day 7, and the infusion did not significantly change how quickly the muscle fatigued.
  • Old mice (Aging Cell, 2025): eight weeks of treatment blunted the rise in frailty and partly reversed declines in heart strain and muscle fatigue resistance, but the authors did not detect significant changes in epigenetic or transcriptomic markers of biological age in most treated groups.
  • Rats with heart failure with preserved ejection fraction (International Journal of Molecular Sciences, 2026): 12 weeks of treatment modestly improved heart mitochondrial respiration, with no functional or structural benefit to the heart.
  • Fertility (Aging Cell, October 2026): researchers in China gave 10-month-old female mice daily injections into the abdominal cavity for seven days. Litter size, fertilisation rate and egg quality improved, but the effect on fertility lasted only one month. In immature eggs from fertility-clinic patients, 54 from 3 women aged 35 or over and 75 from 19 younger women, the authors report better maturation and early development when elamipretide was added to the culture dish. They call elamipretide a candidate for age-related infertility. The study did not give elamipretide to women.

Research vials are not the medicine

On 24 August 2026 the FDA issued warning letters to Peptide Partners, Royal Peptides and Tex Peptides, listing "SS-31 (Elamipretide)" among products it said were unapproved new drugs, alongside products labelled as semaglutide, tirzepatide and retatrutide. In the Royal Peptides letter, the agency said that despite "for research use only" and "not for human or animal consumption" statements, evidence from the website, including bacteriostatic water, a "peptide guide" and a "peptide calculator", showed the products were intended as drugs for human use. The FDA's letters note that injected products bypass some of the body's key defences against toxins and microorganisms.

Our view

  • Elamipretide is a serious mitochondrial drug with a narrow evidence base. Its one approval rests on a muscle-strength measure in an open-label extension of 8 to 10 patients, and its two larger randomised trials missed their primary endpoints.
  • There is no human evidence that elamipretide slows ageing. The best human data in healthy older people show a short-lived rise in a muscle energy measure after one infusion, with no significant change in fatigue.
  • The fertility finding is early. It is a mouse study with a one-month effect and lab work on eggs, and it should not change what anyone does at a fertility clinic today.
  • Do not inject SS-31 bought online. The FDA treats these products as unapproved new drugs. The licensed product carries warnings about serious allergic reactions, including reactions that needed emergency treatment.
  • If you have a mitochondrial disease, ask your specialist about clinical trials rather than self-sourcing.

UAE rules

On 29 July 2026 the Dubai Health Authority issued circular CIR-2026-00000107, "Regulations for Handling Peptide Products in Healthcare Facilities", to all health professionals and facilities under its jurisdiction. A clinic offering peptide injections in Dubai should be DHA-licensed and able to explain how it meets that circular. Forzinity's approval is a US approval for Barth syndrome. Ask a pharmacist at Bin Sina, Supercare or Medicina before combining any peptide with your other medicines, and take fertility questions to a licensed fertility specialist.

FAQ

Is SS-31 the same as elamipretide?

Yes. SS-31 is an earlier research name for elamipretide. The licensed US product is Forzinity, approved for Barth syndrome.

Does SS-31 slow ageing?

There is no human evidence that it does. In old mice it improved heart and muscle function without detectable change in molecular markers of biological age, and in older adults a single infusion did not significantly change muscle fatigue.

Can elamipretide improve fertility?

Only animal and lab data exist. A 2026 study improved fertility in older mice for one month and helped human eggs mature in a dish. It has not been given to women in a fertility trial.

Sources

These are the documents this page relies on.

  1. Zhang HL, Wang Y, Wang C, et al. Elamipretide rejuvenates oocyte quality and restores female fertility during reproductive aging. Aging Cell. 2026;25(10):e70749Aging Cell (PubMed 42827331, PMC13633435)
  2. FDA grants accelerated approval to first treatment for Barth syndrome, 19 September 2025US Food and Drug Administration
  3. FORZINITY (elamipretide) injection, for subcutaneous use: prescribing information (2025)US Food and Drug Administration (Drugs@FDA)
  4. Tung C, et al. Elamipretide: a review of its structure, mechanism of action, and therapeutic potential. Int J Mol Sci. 2025;26(3):944International Journal of Molecular Sciences (PubMed 39940712)
  5. Karaa A, Bertini E, Carelli V, et al. Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial. Neurology. 2023;101(3):e238-e252Neurology (PubMed 37268435)
  6. Karaa A, et al. Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial. Orphanet J Rare Dis. 2024;19(1):431Orphanet Journal of Rare Diseases (PubMed 39574155)
  7. Ehlers JP, et al. ReCLAIM-2: a randomized phase II clinical trial evaluating elamipretide in age-related macular degeneration, geographic atrophy growth, visual function, and ellipsoid zone preservation. Ophthalmol Sci. 2025;5(1):100628Ophthalmology Science (PubMed 39605874)
  8. Roshanravan B, Liu SZ, Ali AS, et al. In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial. PLoS One. 2021;16(7):e0253849PLoS One (PubMed 34264994)
  9. Mitchell W, et al. The mitochondria-targeted peptide therapeutic elamipretide improves cardiac and skeletal muscle function during aging without detectable changes in tissue epigenetic or transcriptomic age. Aging Cell. 2025;24(6):e70026Aging Cell (PubMed 40080911)
  10. Schauer A, et al. Mitochondrial targeting by elamipretide improves myocardial bioenergetics without translating into functional benefits in HFpEF. Int J Mol Sci. 2026;27(2):1060International Journal of Molecular Sciences (PubMed 41596703)
  11. Warning letter: Peptide Partners LLC, MARCS-CMS 735063, 24 August 2026US Food and Drug Administration
  12. Warning letter: Royal Peptides LLC, MARCS-CMS 734884, 24 August 2026US Food and Drug Administration
  13. Warning letter: TXP Innovations LLC dba Tex Peptides, MARCS-CMS 735067, 24 August 2026US Food and Drug Administration
  14. Circular CIR-2026-00000107: Regulations for Handling Peptide Products in Healthcare Facilities, 29 July 2026Dubai Health Authority